coming down to Aroa and Polynovo; Avita seems out of the race for bow, page-32

8 months ago- they were 140 staff, and now 1st July 2021 annual report they are 220 staff- so they are- at my guess after their 50 million cap raise- rapidly expanding in the US- to capitalise the signing of the US GPO Premier (3rd largest)- to help field questions from different hospitals

I notice PNV are also recruiting inside sales people (they are calling them associates)

On a plus side for PNV- generating 44 million sales (20% more than ARX) with 30 % less staff- this is suggesting to me the average sale size is larger than ARX- in the US to date they pretty much have field sales reps- which would also support larger sales size (usually when sales are very small they get in some inside sales people to cover that calling it SMB)

I'd like to see some kind of comparison in the technology/ infection rate/ aesthetics after wound recovery

Does anyone here remember why PNV did not go ahead with its hernia product that was meant to be released earlier?